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PURPOSE: This study was designed to determine whether
the injection of muscle-derived stem cells into the anal
sphincter can improve functional properties in a fecal
incontinence rat model.
METHODS: Cryoinjured rats were utilized as a fecal
incontinence model. The gastrocnemius muscles of
normal three-week-old female Sprague-Dawley rats were
used for the purification of the muscle-derived stem cells.
The experimental group was divided into three sub-
groups: normal control; cryoinjured; and muscle-derived
stem cells (3×10
6 cells) injection group of cryoinjured
rats. All groups were subsequently employed in contrac-
tility experiments using muscle strips from the anal
sphincter, one week after preparation.
RESULTS: Contractility in the cryoinjured group was
significantly lower than in the control after treatment with
acetylcholine and KCl. In the muscle-derived stem cells
injection group, contraction amplitude was higher than in
the cryoinjured group but not significantly (20.5±21.3 vs.
17.3±3.4 g per gram tissue, with acetylcholine (10
−4 mol/l);
31±14.2 vs. 18.4±7.9 g per gram tissue, with KCl
(10
−4 mol/l)). PKH-26-labeled transplanted cells were
detected in all of the grafted sphincters. Differentiated
muscle masses stained positively for alpha smooth muscle
actin and myosin heavy chain at the muscle-derived stem
cells injection sites.
CONCLUSIONS: This is the first study reporting that
autologous muscle-derived stem cell grafts may be a tool
for improving anal sphincter function.
KEY WORDS: Fecal incontinence; Muscle-derived stem cell;
Anal sphincter; Rat; Cryoinjury; Contractility.
F
ecal incontinence (FI) remains a socially isolating
condition, which can have a profound impact on all
aspects of quality of life. A systematic review on the
prevalence of FI in community-dwelling adults has shown
thattheestimatedprevalencevariedfrom 0.4to18percent.
1
The most common cause of FI is damage to the anal
sphincter or nerve complex resulting from disease process
or traumas, including obstetric injuries and anorectal
surgery. One surgical approach to the treatment of FI has
been bulking agents for the augmentation of muscle bulk
and to restore sphincter anatomy in sites in which it is
deficient, or circumferentially in cases in which the whole
muscle was degenerate. Since the initial report in 1993,
2
several agents have been used in the treatment of FI with
glutaraldehyde cross-linked collagen,
3 autologous fat,
4 inject-
able silicone,
5–8 and carbon beads.
9–11 Injection therapy im-
proved the patient’ss y m p t o m s
2–11 in nonrandomized studies,
although the reported improvements in resting or squeeze
pressure remain controversial. However, the efficacy of inject-
able agents is limited by several factors, including reabsorp-
tion, allergic reactions, and migration, even when injection
therapy is utilized for the treatment of urinary incontinence.
10
Clearly, “living” contractile bulking agents, which improve
sphincter muscle function, would be ideal, because conven-
tional bulking agents exert only a “bulk” effect, without
effecting any improvements in anal sphincter contractility.
There are several reports about muscle-derived stem
cells, but the definition of muscle-derived stem cells
(MDSC) is still unclear. Satellite cells play a central role in
regeneration of skeletal muscle, and a recent study showed
thatsatellite cellsarea heterogeneouspopulationcomposed
of stem cells and committed progenitors.
12,13 The injection
of MDSC into the periurethral sphincter was effective in a
rat urinaryincontinencemodel.
14–20Recently, Strasseretal.
demonstrated that injection therapy using autologous
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collagen injection for the treatment of stress urinary
incontinence in women in a randomized, controlled trial.
21
However, the question as to whether these MDSC are
bulkingtheurethraorpromotingthefunctionalrecoveryof
the injured sphincter remains to be satisfactorily answered.
In the coloproctology field, some authors have demon-
strated that autologous stem cells obtained from a lipoas-
piratemaybeutilizedforthetreatmentoffistulasinCrohn’s
disease without any adverse effects.
22,23 Shafik
4 has shown
that perianal fat injection was effective in the treatment of
partial fecal incontinence with no fat migration or embo-
lism. Until recently, no studies have been conducted to
determine the functional and histologic effects that occur
aftertheinjectionofstemcellsintotheanalsphincterinaFI
animal model. In the present study, we have attempted to
determinewhetherinjectedMDSCcaneffectimprovements
in the functional properties of a rat FI model.
MATERIALS AND METHODS
The Animal Care and Use Committee of Seoul National
University Bundang Hospital approved all procedures
performed on animals (Protocol No. 64-2007-028). All
experiments were conducted using normal three-week-old
(200–250 g) female Sprague-Dawley (SD) rats. Three
groups were used: a normal control group that received
no injections; a cryoinjured group; and a MDSC injection
group of cryoinjured rats. The MDSC injection group was
subjected to cryoinjury and MDSC injection under single
anesthetic conditions. All groups were subsequently sub-
jected to contractility experiments one week later.
MDSC Purification and Characterization
MDSC were harvested from the gastrocnemius muscles of
rats and purified via the preplate technique.
24 The muscle
biopsy was obtained from the hind limb and was minced
into a coarse slurry with successively smaller needles. The
cells were then enzymatically dissociated via the addition of
collagenase type XI 0.2 percent (Sigma, St. Louis, MO) for
1 hour at 37°C, 240 units of Grade II dispase (Gibco-BRL,
Grand Island, NY) for 45 minutes, and trypsin 0.1 percent
(Gibco-BRL)for30minutes.Thedissociatedcellswerethen
preplated on collagen and poly-D-lysin (Sigma, St. Louis,
MO)-coated flasks. The early preplated cells and fibroblasts
were observed to adhere to the first flask. The early plated
cellswerediscardedbecausetheydonotproliferatewell,and
they survive poorly after transplantation. All cells that failed
to adhere to the flask were then transferred to another flask
for approximately one hour and were serially transferred
and incubated.
24 The cells used in this experiment were
obtained from the last preplate. For the characterization of
cultured cells, predetermined optimal amounts of rat anti-
mouse monoclonal antibodies (CD-34, CD-45, Desmin)
were directly added to each tube for 30 minutes. The
proliferation medium used to grow the cells was Dulbecco’s
modified Eagle medium (Gibco-BRL) supplemented with
10 percent fetal bovine serum (Gibco-BRL), 10 percent
horse serum (Gibco-BRL), 0.5 percent chick embryoextract
(Sera Laboratories International Ltd, UK), and 1 percent
penicillin/streptomycin(Gibco-BRL).Forthelabelingofthe
MDSC,PKH-26dye(analiphaticfluorescentchromophore,
Sigma) was used to label the cells before their injection,
which is a lipophilic fluorescent dye that binds irreversibly
to the cell membrane and is not transferable to other cells.
Cryoinjury in Anal Sphincter of Rat and Autologous
MDSC Injection
The cryoinjured group and the MDSC injection group
were administered ketamine (80 mg/kg), and after
appropriate induction, cryoinjury of the anal sphincter
was induced using an aluminum rod with a diameter of
2 mm, which was chilled with liquid nitrogen. The chilled
probe was positioned against the right hemisphere of the
anal sphincter for 30 seconds. This mode of injury is the
modification of a previously described procedure.
25
Approximately five minutes after the injury, MDSC
suspended in Hanks’ balanced salt solution (Gibco-BRL;
3×10
6 cells per 100 μl) was injected manually into the
middleanalsphincteroftheMDSCgroupratsusinga50μl
Hamilton microsyringe (25 gauge needle; Hamilton, Reno,
NV) with microscopic guidance. Three injections per rat
(30μleach)wereperformedontherighthemisphereofthe
anal sphincter, which had been subjected to cryoinjury.
Preparation of Muscle Strips and Contractility Test
Each group underwent contractility experiments at one
week after surgery. After anesthetic induction in all groups,
the anal sphincter was trimmed and transferred into a bath
perfused with phosphate-buffered saline. The transverse
loop of the sphincter was incised on the left side, and each
strip measured approximately 1×1×10 mm (width and
length). The muscle strips were tied with 3-0 silk sutures to
a glass hook, and the other end was connected to a Grass
Force Transducer (FT03, GrassInstruments, Quincy, MA),
which was connected to an amplifier (P-122, Grass). The
strips were mounted in a 20 ml bath containing Tyrode’s
solution (116 mM NaCl, 5 mM KCl, 5 mM HEPES, 1 mM
MgCl2, 24 mM NaHCO3, 2 mM CaCl2, and 11.5 mM
glucose) at 37°C and were equilibrated with constant
bubbling with a mixture of 95 percent O2-5 percent CO2.
Thestripswereequilibratedfor30minutesat2gresting
tension for the recordingof isometric tensionin superfusion
organ baths. The strips were then stimulated for 20 seconds
at 32 Hz with 1 millisecond pulses at 80 V using an S48
(Grass Instruments) stimulator. After electrical field stimu-
lation, acetylcholine (Ach) (10
−4 mol/l) or KCl (10
−4 mol/l)
was added to the organ baths to determine the contractile
activities of the anal sphincter. A small air bubble was intro-
duced as each drug was administered to ensure minimal
KANG ET AL:S TEM-CELL THERAPY AFTER SPHINCTER INJURY 1368mixing and/or dilution of the drug. For KCl treatment after
Ach, the strips were washed three times in fresh buffer.
Twitch contractions were determined with strain-gauge trans-
ducers and recorded on a Model 7D Polygraph. The analog
signals obtained from the Force Transducer were converted to
digital signals at a 3 Hz sampling rate (Polyview, Grass) and
were stored in a computer database for further analysis.
Immunohistochemical Staining
Immediately after the recording of isotonic tension, the strips
were weighed and frozen in liquid nitrogen. Serial 5 μm
thickness cryostat sections were obtained around each of the
injection sites, stained with hematoxylin/eosin (H/E), exam-
ined microscopically and additionally via fluorescence micros-
copy for the detection of PKH-26-labelled cells, and
photographed.ThecytoplasmofPKH-26-labeledcellsshowed
red fluorescence as detected by fluorescence microscopy,
whereas the nucleus remained unstained. PKH-26-labeled
cells are usually considered viable because the dye leaves the
cell membrane after cell death.
26 Myonuclei were visualized
with 4′,6-diamidine-2-phenylindole (DAPI). Immunohisto-
chemical staining also was conducted for alpha-smooth
muscle actin (SMA) monoclonal antibody (diluted to 1:100;
Sigma) and myogenin monoclonal antibody (diluted 1:200;
InVitroGen). To evaluate the immune-privileged behavior of
injected cells in MDSC rats, immunohistochemical staining to
detect CD3 marker was performed with a positive control of a
normalrat.MusclestripsoftheanalsphincterunderwentCD3
staining after harvest. The primary antibody was a mouse
monoclonal antibody against CD3 that was incubated for one
hour at room temperature. The CD3 is a pan-T-cell marker
that is positive for CD4 and CD8 lymphocytes.
Statistical Analysis
Contractility data are expressed as means ± standard
deviations. Paired t-tests were used for comparison
between data at one week. P<0.05 was considered to be
statistically significant. All calculations were conducted by
using SPSS
® 11.0 software (SPSS, Inc., Chicago, IL).
RESULTS
Characterization of MDSC
We isolated MDSC from rat gastrocnemius muscles, and
the cells were characterized via immunostaining. The
MDSC were determined to evidence stem-cell character-
istics (CD34+) and were not of hematogenous (CD45-)
but rather myogenic origin (desmin+).
14,27 They were used
for further experiments as MDSC.
Contractility
The maximal contraction amplitude of the anal sphincter
strip in the cryoinjured group was statistically significantly
lower than in the normal control group after Ach
(10
−4 mol/l) and KCl (10
−4 mol/l) treatment (17.3±3.4 vs.
35.1±6.2 g per gram tissue, P=0.001; 18.4±7.9 vs. 46.9±
14.1 g per gram tissue, P=0.006, respectively; Table 1).
Representative examples of anal sphincter contractility
studies after Ach (10
−4 mol/l) treatment are shown in
Fig. 1a-c. In the MDSC injection group, the contraction of
thesphincterstrip washigherthan in thecryoinjured group
after treatment with Ach (10
−4 mol/l) and KCl (10
−4 mol/l)
treatment, but this was not significantly different (20.5±
21.3 vs. 17.3±3.4 g per gram tissue, P=0.748; 31±14.2 vs.
18.4±7.9 g per gram tissue, P=0.120, respectively).
Histologic Findings
The anal sphincters of the normal control group harbored
both smooth and skeletal muscle (Fig. 2a). A layer of outer
striated muscle fibers encircles the smooth muscle layers.
Thecryoinjuredgroupshoweddamagedmusclefiberswith
cytoplasmic vacuolization and focal interstitial inflamma-
tory cell infiltration (Fig. 2b). Regenerating muscle fibers
with enlarged nuclei were observed in the variable
orientation at the muscle-derived stem cell injection site
(Fig. 2c). PKH-26-labeled transplanted cells were detected
in all of the grafted sphincters at seven days after injection
(Fig. 3). Regenerating myofibers of smooth and skeletal
muscle stained positively for alpha-SMA and myosin
heavy-chain (MHC) at the MDSC injection sites. There
was no observed immune response, such as lymphocytic
infiltration, vasculitis, or single-cell apoptosis, around the
site of MDSC injection. CD3 staining was not observed at
MDSC injection sites at seven days (Fig. 4).
DISCUSSION
Injection therapy for the treatment of anal sphincter con-
tractility defects is a minimally invasive procedure, which
can be readily and rapidly performed by an experienced
Table 1. Contractility of muscle strips
Acetylcholine (10
−4 mol/l) KCl (10
−4 mol/l)
n g per mg tissue P value g per mg tissue P value
Normal rats 5 35.1±6.2 0.001* 46.9 ± 14.1 0.006*
Cryoinjured rats 5 17.3±3.4 0.748
† 18.4±7.9 0.12
†
Cryo with MDSC 5 20.5±21.3 31±14.2
MDSC = muscle-derived stem cells; Cryo with MDSC = cryoinjured rats treated with muscle-derived stem cells.  *P value for comparison between Normal rats and Cryoinjured
rats.  †P value for comparison between Cryoinjured rats and Cryo with MDSC.
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However, the injectable agents have potential disadvan-
tages, including the need for multiple injections, allergic
reactions caused by foreign agents, and migration. Stem-
cell therapy as a “living” contractile bulking agent may be
an ideal tool, which is unlikely to result in migration
problems, as have been associated with Teflon, Silicon, and
Durasphere.
10
In the present study, we used a highly specific pop-
ulation of cells that evidence stem cell features compared
with myoblasts. These cells were highly purified MDSC,
which were identified via immunohistochemical staining
as CD34+, CD45-, and desmin+.
13,28,29 These cells have
been reported to evidence an improved survival rate
posttransplantation because they do not trigger immune
reactions as do regular myoblasts after injection.
28 In this
study, injection of autograft MDSC was immunologically
inert. MDSC do not fuse quickly with each other and have
been shown to be capable of proliferating more efficiently.
In the current study, we attempted to determine whether
injected MDSC could survive in the anal sphincter,
differentiate into myofibrils, and ultimately enhance
contractility. The injected PKH-26-labeled MDSC have
shown improved survival compared with myoblasts, which
do not survive beyond 48 hours after injection.
28 MDSC
are reported to be durable and have been demonstrated to
survive in the lower urinary tract for up to six months
postinjection.
30
We demonstrated that the MDSC had integrated
within the muscle layer of the cryoinjured anal sphincter
and that new muscle fiber had formed at the sphincter
injection sites, as evidenced by histologic examination.
This study verified that differentiated muscle cells originate
from transplanted cells via the colocalization of injected
muscle-derived stem cell with PKH-26-staining and
muscles, as shown by the immunostaining of MHC or
alpha-SMA.Itmeansthatautologousskeletalcellgraftscan
switch to slow-twitch fibers.
31
In this study, the FI rat model was validated because
the contraction amplitudes of the cryoinjured rats were
significantly lower than those of normal control rats. Using
this cryoinjured animal model, we evaluated the effects of
MDSC injected into cryoinjured anal sphincter tissue via
measurements of the contractility of the muscle strips. In
thecurrentstudy, MDSCwere consideredto havepotential
as a functional bulking agent on the basis of contractility
FIGURE 2. Hematoxylin-eosin staining. a. Normal histology of the anal sphincter in normal control rats. Internal smooth muscle
(arrowhead) and external skeletal muscle (arrow) (magnification, ×10). b. Damaged muscle fibers with cytoplasmic vacuolization and
focal interstitial inflammatory cell infiltration in the cryoinjured group (magnification, ×400). c. Regenerating muscle fibers in the
variable orientation with enlarged nuclei at the muscle-derived stem cell injection site (magnification, ×400).
a
b
c
FIGURE 1. Representative contractility recording of muscle strips
treated with acetylcholine. a. Normal control with acetylcholine. b.
Cryoinjured group with acetylcholine. c. Muscle-derived stem cell
injection group with acetylcholine.
KANG ET AL:S TEM-CELL THERAPY AFTER SPHINCTER INJURY 1370FIGURE 4. CD3 staining. a. Scattered CD3-positive T cells (brown color) in anal mucosa of normal rat. b. CD3 staining was not observed
after MDSC injection (magnification, ×200).
FIGURE 3. Muscle formation in the cryoinjured anal sphincter following muscle-derived stem cell injection. a-c. Normal control group
shows a thick smooth muscle layer encircled by a layer of outer striated muscle fibers. d-f. Cryoinjured group shows weakened smooth
muscle and skeletal muscle layer. G. Muscle-derived stem cell injection group shows the variable orientation of the new muscle fiber. h.
Differentiated smooth muscle (yellow) shown in colocalization of injected muscle-derived stem cell injection (PKH-26-staining, red) and
smooth muscle via the immunostaining of alpha smooth muscle actin (green). i. Differentiated skeletal muscle (yellow) shown in the
colocalization of injected muscle-derived stem cell injection (PKH-26-staining, red) and skeletal muscle via immunostaining of myosin
heavy-chain (green). Hematoxylin-eosin staining (a, d, g), immunostaining of alpha smooth muscle actin (b, e, h), and myosin heavy-
chain (c, f, i) (magnification, ×100).
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significantly. This insignificant result may be attributed to
the following points. First, this study involved small
volume injections of 3×10
6 MDSC. We believe that more
MDSC should be injected for FI, which differs from
urinary incontinence with regard to muscle bulk. Second,
contractility is representative of the functioning of the
active components of the anal sphincter. Itremains unclear
as to whether MDSC autografting would restore sphincter
muscle function or simply function as a simple bulking
agent. It should be determined in the future whether
injected MDSC develop into functional tissue, thus result-
ing in increased contractility. Third, it remains to be
determined whether injected MDSC differentiate into
myofibers for contraction with reinnervation. The results
of some animal studies have indicated that muscle
reinnervation may be possible via electrical stimulation,
or the addition of fibroblasts or Schwann cells.
15,32,33 Yiou
et al.
16 also demonstrated that the maturation of muscle
precursor cells activated nerve regeneration and restored
functional motor units. Although adult skeletal muscle in-
cludes a population of progenitor stem cells that can generate
cells of the myogenic lineagea n dc e l l sw i t hn e u r o g e n i c
properties,
34 it remains to be determined whether stem cells
can induce the functional reinnervation of regenerated
muscles. Fourth, MDSC injection therapy may have certain
disadvantages, including migration and reabsorbtion, as is the
case with other commercial injection agents. Fifth, the
insignificance could simply be a Type II error, with only five
rats in each group, although the trends were actually quite
s t r o n g .S i x t h ,A c ho rK C lw a sa d d e dt ot h eo r g a nb a t h st o
determine the contractile activities of the anal sphincter in
this study. We think that some agents may induce a greater
effective stimulation of muscle other than KCl or Ach, which
might give a significant improvement in muscle contractility.
The current study was for a short-term period.
Although we have demonstrated engraftment of MDSC in
the injury site, it remains to be determined whether MDSC
would continue to differentiate over time. The risk of
tumor formation or adequate functionalimprovement may
be determined in the future via al o n g - t e r ms t u d y .
However, we considered that a long-term period, in which
sphincter regeneration may be induced by the intrinsic
satellite cells, may be a bias factor. In this study, the FI rat
model was validated, although the animal model utilized
herein is not perfect. This is the first study reporting that
autologous MDSC grafts may be used as a tool for im-
proving anal sphincter contractility.
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